1. High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines
- Author
-
Kristin E. Williams, Kathleen F. Arcaro, Maxwell P. Lee, Brian T. Pentecost, and Douglas L. Anderton
- Subjects
Antimetabolites, Antineoplastic ,Cancer Research ,Antineoplastic Agents, Hormonal ,Estrogen receptor ,Breast Neoplasms ,Biology ,Breast cancer ,Antigens, Neoplasm ,Cell Line, Tumor ,medicine ,Humans ,Promoter Regions, Genetic ,skin and connective tissue diseases ,Molecular Biology ,Oligonucleotide Array Sequence Analysis ,Estrogen Antagonists ,Estrogen Receptor alpha ,Cancer ,Methylation ,DNA Methylation ,Antiestrogen ,medicine.disease ,Molecular biology ,Neoplasm Proteins ,Repressor Proteins ,Tamoxifen ,CpG site ,Drug Resistance, Neoplasm ,DNA methylation ,Azacitidine ,Cancer research ,CpG Islands ,Female ,Research Paper ,medicine.drug - Abstract
Roughly two-thirds of all breast cancers are ERα-positive and can be treated with the antiestrogen, Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 y. Aberrant DNA methylation, an epigenetic mechanism that alters gene expression in cancer, is thought to play a role in this resistance. To develop an understanding of Tamoxifen-resistance and identify novel pathways and targets of aberrant methylation, DNA from MCF-7 breast cancer cells and Tamoxifen-resistant derivatives, TMX2-11 and TMX2-28, were analyzed using the Illumina HumanMethylation450 BeadChip. Normalizing against MCF-7 values, ERα-positive TMX2-11 had 4000 hypermethylated sites and ERα-negative TMX2-28 had over 33 000. Analysis of CpG sites altered in both TMX2-11 and TMX2-28 revealed that the Tamoxifen-resistant cell lines share 3000 hypermethylated and 200 hypomethylated CpGs. ZNF350 and MAGED1, two genes hypermethylated in both cell lines, were examined in greater detail. Treatment with 5-aza-2ꞌdeoxycitidine caused a significant reduction in promoter methylation of both ZNF350 and MAGED1 and a corresponding increase in expression in TMX2-28. A similar relationship between methylation and expression was not detected in TMX2-11. Our findings are indicative of the variable responses to methylation-targeted breast cancer therapy and highlight the need for biomarkers that accurately predict treatment outcome.
- Published
- 2013
- Full Text
- View/download PDF